RaviSalgiaMDPhD

Oncology • Duarte, CA

Professor and Chair, Department of Medical Oncology & Therapeutics Research at City of Hope

Join to view full profile

Dr. Salgia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salgia's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-218-3712

Fax+1 626-471-7322

Summary

I am board-certified in both internal medicine and medical oncology. Currently I am the Arthur & Rosalie Kaplan Chair in Medical Oncology and the associate director for clinical sciences in City of Hope's Comprehensive Cancer Center. I also serve on various panels for the National Cancer Institute. I've consistently received research grants from the NIH for my research work and have been awarded several invention discoveries and patents. I am also the current Chief Editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis.

Prior to joining City of Hope, I served as tenured professor of medicine, pathology and dermatology; director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology; vice chair for translational research in the department of medicine; and associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1987 - 1990
Loyola University Chicago Stritch School of MedicineClass of 1987, MD
Loyola University Chicago Stritch School of MedicinePhD, 1985

Certifications & Licensure

CA State Medical License 2016 - 2025
IL State Medical License 2003 - 2017
MA State Medical License 1990 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Chicago Magazine: Top Doctors Castle Connolly, 2012, 2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2003 Apr 01
Completed
Phase 2
Study of Tumor Samples From Patients With Lung Cancer Start of enrollment: 2008 Sep 01
Completed
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Start of enrollment: 2012 Feb 29
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jan 16
Terminated
Phase 2
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14
Terminated
Phase 2
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2018 Dec 01
Withdrawn
Phase 2
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer Start of enrollment: 2021 Sep 01
Recruiting
Phase 1
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2021 May 28
Recruiting
Phase 1
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer Start of enrollment: 2020 Dec 31
Completed
Phase 2
Roles: Principal Investigator, Contact
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2024 Apr 24
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.
Amanda Reyes, Michelle Afkhami, Erminia Massarelli, Jeremy Fricke, Isa Mambetsariev
Clinical Lung Cancer. 2024-12-01
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential.
Pankaj Garg, Sravani K Ramisetty, Ayalur Raghu Subbalakshmi, B Madhu Krishna, Siddhika Pareek
Biochemical Pharmacology. 2024-11-01
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Bridget E Crossman, Regan L Harmon, Kourtney L Kostecki, Nellie K McDaniel, Mari Iida
Journal of Clinical Medicine. 2024-10-10

Other

Chemoprevention of lung cancer
Salgia R, Skarin AT
http://www.uptodate.com/contents/chemoprevention-of-lung-cancer
UpToDate, Wolters Kluwer Health - 2012-01-17

Press Mentions

Association of Community Cancer Centers Releases 16 Abstracts This FallNovember 13th, 2020
10 Health Myths: O.C. Doctors and Experts Give Us Their TakeAugust 10th, 2020
Prior PD-1 Blockade Did Not Appear to Influence the Severity of COVID-19 in Patients with Lung CancerJune 17th, 2020
Join now to see all